Vogt-koyanagi-harada disease: Clinical and demographic characteristics of patients in a specialized eye hospital in Turkey

Ocular Immunology and Inflammation

Volumn 22, Issue 4, 2014, Pages 277-286

  Ozdal, Pinar ^a   Ozdamar, Yasemin ^a   Yazici, Alper ^b   Teke, Mehmet Y ^a   Ozturk, Faruk ^a  

^a Ophthalmology Department   (Turkey)

^b BALIKESIR UNIVERSITY   (Turkey)

Author keywords

Ocular involvement; Treatment; Uveitis; VKH; Vogt Koyanagi Harada disease

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; METHOTREXATE; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ALOPECIA; ARTICLE; CATARACT; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DEMOGRAPHY; DISEASE COURSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLAUCOMA; HEADACHE; HUMAN; HYPEREMIA; IMMUNOSUPPRESSIVE TREATMENT; IRIDOCYCLITIS; MALE; OUTCOME ASSESSMENT; PAPILLITIS; RECURRENT DISEASE; RETINA DETACHMENT; RETINA EDEMA; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; TINNITUS; TREATMENT RESPONSE; TURKEY (REPUBLIC); UVEITIS; VITILIGO; VITRITIS; VOGT KOYANAGI SYNDROME; AGE DISTRIBUTION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; INCIDENCE; OPTICAL COHERENCE TOMOGRAPHY; SEX RATIO; TURKEY; UVEOMENINGOENCEPHALITIC SYNDROME;

ADULT; AGE DISTRIBUTION; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INCIDENCE; MALE; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; TOMOGRAPHY, OPTICAL COHERENCE; TURKEY; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 84904324399     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2013.856448     Document Type: Article

References (37)

1. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265-292
2. Read RW, Rao NA, Cunningham ET. Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol. 2000;11:437-442
3. Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1980:90:69-75
4. Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 1996;80:1002-1008
5. Sugita S, Sagawa K, Mochizuki M, et al. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int Immunol. 1996;8: 799-803
6. Rao NA. Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. Eye (Lond). 1997; 11:213-216
7. Yamaki K, Gocho K, Hayakawa K, et al. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000;165:7323-7329
8. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647-652
9. Rajendram R, Evans M, Rao NA. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2005;45:115-134
10. Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131:599-606
11. Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome: Clinical course, therapy, and long-Term visual outcome. Arch Ophthalmol. 1991;109:682-687
12. Bykhovskaya I, Thorne JE, Kempen JH, et al. Vogt-Koyanagi-Harada disease: Clinical outcomes. Am J Ophthalmol. 2005;140:674-678
13. Forster DJ, Rao NA, Hill RA, et al. Incidence and management of glaucoma in Vogt-Koyanagi-Harada syndrome. Ophthalmology. 1993;100:613-618
14. Kuo IC, Rechdouni A, Rao NA, et al. Subretinal fibrosis in patients with Vogt-Koyanagi-Harada disease. Ophthalmology. 2000;107:1721-1728
15. Al-Kharashi AS, Aldibhi H, Al-Fraykh H, et al. Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27:201-210
16. Tugal-Tutkun I, Ozyazgan Y, Akova YA, et al. The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey. Int Ophthalmol. 2007;27:117-123
17. Murthy SI, Moreker MR, Sangwan VS, et al. The spectrum of Vogt-Koyanagi-Harada disease in South India. Int Ophthalmol. 2007;27:131-136
18. Riddington L, Hall AJ, Tait B, et al. Vogt-Koyanagi-Harada syndrome in patients of Vietnamese ancestry. Aust N Z J Ophthalmol. 1996;24:147-149
19. Chee SP, Jap A, Bacsal K. Spectrum of Vogt-Koyanagi-Harada disease in Singapore. Int Ophthalmol. 2007;27: 137-142
20. Tesavibul N, Sansanayuth W. Vogt-Koyanagi-Harada disease in Thai patients. J Med Assoc Thai. 2005;88:26-30
21. Ozdal P, Yazici A, Tufek M, Ozturk F. Epidemiology of uveitis in a referral hospital in Turkey. Turk J Med Sci. In press
22. Khairallah M, Zaouali S, Messaoud R, et al. The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa. Int Ophthalmol. 2007;27:125-130
23. Yang P, Zhang Z, Zhou H, et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr Eye Res. 2005;30:943-948
24. Yamaki K, Hara K, Sakuragi S. Application of revised diagnostic criteria for Vogt-Koyanagi-Harada disease in Japanese patients. Jpn J Ophthalmol. 2005;49:143-148
25. Tabbara KF, Chavis PS, Freeman WR. Vogt-Koyanagi-Harada syndrome in children compared to adults. Acta Ophthalmol Scand. 1998;76:723-726
26. Sugiura S. Some observations on uveitis in Japan, with special reference to Vogt-Koyanagi-Harada and Behcet diseases. Nihon Ganka Gakkai Zasshi. 1976;80:1285-1326
27. Yang P, Ren Y, Li B, et al. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114:606-614
28. Rao NA, Gupta A, Dustin L, et al. Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. Ophthalmology. 2010;117:591-599
29. Lertsumitkul S, Whitcup SM, Nussenblatt RB, et al. Subretinal fibrosis and choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Graefes Arch Clin Exp Ophthalmol. 1999;237:1039-1045
30. Sukavatcharin S, Tsai JH, Rao NA. Vogt-Koyanagi-Harada disease in Hispanic patients. Int Ophthalmol. 2007;27: 143-148
31. Ohno S, Minakawa R, Matsuda H. Clinical studies of Vogt-Koyanagi-Haradas disease. Jpn J Ophthalmol. 1988;32: 334-343
32. Rao NA. Treatment of Vogt-Koyanagi-Harada disease by corticosteroids and immunosuppressive agents. Ocul Immunol Inflamm. 2006;14:71-72
33. Read RW, Yu F, Accorinti M, et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006;142:119-124
34. Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14:87-90
35. Mondkar SV, Biswas J, Ganesh SK. Analysis of 87 cases with Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol. 2000;44:296-301
36. Agarwal M, Ganesh SK, Biswas J. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2006;14:333-339
37. Arcinue CA, Radwan A, Lebanan MO, et al. Comparison of two different combination immunosuppressive therapies in the treatment of Vogt-Koyonagi-Harada syndrome. Ocul Immunol Inflamm. 2013;21:47-52.